Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment.

ABSTRACT:

Background

Despite the efficacy of immune checkpoint inhibitors (ICIs) only the 20-30% of treated patients present long term benefits. The metabolic changes occurring in the gut microbiota metabolome are herein proposed as a factor potentially influencing the response to immunotherapy.

Methods

The metabolomic profiling of gut microbiota was characterized in 11 patients affected by non-small cell lung cancer (NSCLC) treated with nivolumab in second-line treatment with anti-PD-1 nivolumab. The metabolomics analyses were performed by GC-MS/SPME and ¹H-NMR in order to detect volatile and non-volatile metabolites. Metabolomic data were processed by statistical profiling and chemometric analyses.

Results

Four out of 11 patients (36%) presented early progression,

SUBMITTER: Botticelli A 

PROVIDER: S-EPMC6998840 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature